Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q3 FY26 results · Oct–Dec 2025

Dr. Reddy's Laboratories reported revenue from operations of ₹8,753.40 crore (up 4.4% from Q3 FY25) and net profit of ₹1,189.60 crore (down 15.3% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	8,753.40	8,381.20	+4.4%	8,828.30	−0.8%
Other income	268.80	150.20	+79.0%	323.90	−17.0%
Total income	9,022.20	8,531.40	+5.8%	9,152.20	−1.4%
Profit before share of associates & JVs and tax	1,540.90	1,870.10	−17.6%	1,738.50	−11.4%
Share of profit/(loss) of associates & JVs	2.30	4.20		6.30
Net profit for the period	1,189.60	1,404.20	−15.3%	1,336.80	−11.0%
Attributable to shareholders of the company	1,209.90	1,413.70	−14.4%	1,347.10	−10.2%
EPS, basic (₹)	14.53	16.97	−14.4%	16.18	−10.2%
Net margin (%)	13.6	16.8		15.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	4,282.70	5,015.00	−14.6%	4,618.60	−7.3%
Other income	360.30	235.40	+53.1%	364.20	−1.1%
Total income	4,643.00	5,250.40	−11.6%	4,982.80	−6.8%
Profit before tax	104.20	1,119.40	−90.7%	516.30	−79.8%
Net profit for the period	90.60	849.40	−89.3%	387.30	−76.6%
EPS, basic (₹)	1.09	10.20	−89.3%	4.65	−76.6%
Net margin (%)	2.1	16.9		8.4

Consolidated

Filed with BSE: 21 Jan 2026, 19:31 IST
Board meeting: 21 Jan 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 21 Jan 2026, 19:31 IST
Board meeting: 21 Jan 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE